Literature DB >> 25415310

Economic burden of heart failure: investigating outpatient and inpatient costs in Abeokuta, Southwest Nigeria.

Okechukwu S Ogah1, Simon Stewart2, Obinna E Onwujekwe3, Ayodele O Falase4, Saheed O Adebayo5, Taiwo Olunuga5, Karen Sliwa6.   

Abstract

BACKGROUND: Heart failure (HF) is a deadly, disabling and often costly syndrome world-wide. Unfortunately, there is a paucity of data describing its economic impact in sub Saharan Africa; a region in which the number of relatively younger cases will inevitably rise.
METHODS: Heath economic data were extracted from a prospective HF registry in a tertiary hospital situated in Abeokuta, southwest Nigeria. Outpatient and inpatient costs were computed from a representative cohort of 239 HF cases including personnel, diagnostic and treatment resources used for their management over a 12-month period. Indirect costs were also calculated. The annual cost per person was then calculated.
RESULTS: Mean age of the cohort was 58.0 ± 15.1 years and 53.1% were men. The total computed cost of care of HF in Abeokuta was 76, 288,845 Nigerian Naira (US$508, 595) translating to 319,200 Naira (US$2,128 US Dollars) per patient per year. The total cost of in-patient care (46% of total health care expenditure) was estimated as 34,996,477 Naira (about 301,230 US dollars). This comprised of 17,899,977 Naira- 50.9% ($US114,600) and 17,806,500 naira -49.1%($US118,710) for direct and in-direct costs respectively. Out-patient cost was estimated as 41,292,368 Naira ($US 275,282). The relatively high cost of outpatient care was largely due to cost of transportation for monthly follow up visits. Payments were mostly made through out-of-pocket spending.
CONCLUSION: The economic burden of HF in Nigeria is particularly high considering, the relatively young age of affected cases, a minimum wage of 18,000 Naira ($US120) per month and considerable component of out-of-pocket spending for those affected. Health reforms designed to mitigate the individual to societal burden imposed by the syndrome are required.

Entities:  

Mesh:

Year:  2014        PMID: 25415310      PMCID: PMC4240551          DOI: 10.1371/journal.pone.0113032

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Heart failure (HF) has recently emerged as a global health problem [1]. It is a highly symptomatic syndrome that affects 2–3% of the population in high income countries especially in people above the age of 65 years [2], [3]. Approximately 15 million (out of 900 million) Europeans and 5.8 million (out of 300 million) Americans are affected by HF [4], [5]. The burden of HF has increased due to increasing elderly population as well as improved survival of patients with risks of HF such as acute myocardial infarction, hypertension and diabetes mellitus [6], [7]. In response, strategies for the effective management of the disease in the outpatient setting have been developed and applied [5]. This has led to improved survival in some countries [4], [8], [9]. In high-income countries, the economic burden of HF is high because it is associated with frequent hospital admissions [10], [11]. Moreover, management of HF places significant financial burden on patients, their families/care-givers and, as indicated, society as a whole [10], [12], [13]. Until recently, little was known about the emerging problem of non-communicable forms of HF supplementing traditional pathways to the syndrome in sub-Saharan Africa. Contemporary studies from South Africa[14], [15] and Nigeria[16]–[19] have built on historical reports to demonstrate that the aetiology, natural history and indeed case profile of HF (i.e. more women and younger individuals affected in the prime of their life) is different from high-income countries. As such, HF is now responsible for 7–10% of medical admissions in the region [16], [19], [20]. Significantly, given its potential enormous cost implications (both related to direct health care costs and economic burden on affected individuals and their families) there is virtually no data on the economic burden of HF in sub-Saharan African countries and major populaces such as Nigeria.

Study Aims & Objectives

The aim of this study, therefore, was to determine the consumption of health care resources for the treatment of HF in Abeokuta, Nigeria and to estimate overall healthcare costs associated with its management in a large and representative cohort of affected cases. Data were used to estimate the annual cost of HF in the region to inform health care policy towards efficient use of resources to mitigate the individual to societal impact of the syndrome.

Material and Methods

Ethics Statement

This study was approved by the Federal Medical Center Abeokuta and University of Witwatersrand Health Research Ethics Review Committees and all the participants provided informed consent in writing, in accordance with the Declaration of Helsinki [21].

Study site

The study was undertaken at the Federal Medical Centre, Abeokuta, Ogun state, southwest Nigeria. The state has a population of about 3,751,140 inhabitants [22]. Abeokuta is the state capital and has a population of about a million people [23]. As described previously [19], Federal medical center Abeokuta is a tertiary institution that receives referrals from primary and secondary health facilities within and outside the state. All the patients that were discharged alive were given monthly appointments for clinical review as well as for refill of their medications. Patients pay out of pocket and many may not be able to buy medication that will last for longer period. Home based nursing care is not in existence in the city and in many parts of the country. Patients are often taken care of by their relations. Healthcare cost in the city of Abeokuta and in most parts of Nigeria is generally borne by the patient through out of pocket payment payments. Only a small proportion of the Nigerian population has access to social health insurance [24]–[26]. However, there exist very strong family bonding and extended family systems where poor patients are assisted by their wealthy or well-to-do family members. The limited coverage of social health insurance in Nigeria is a very big challenge to the achievement of universal health coverage and health care delivery in the country.

Study design and sample

As described previously [19], the Abeokuta HF registry was a hospital based, prospective, observational registry that ran from January 2009 to December 2010 which was established to determine the current clinical profile of HF in the city as well as to assess typical clinical outcomes and healthcare costs (the focus of this report) associated with HF. A more detailed description of the registry has been documented [19]. Briefly, all cases of HF presenting to the hospital were captured into the database. Private health facilities, primary health centres as well as health workers were sensitized on the existence of the registry with good response. To a large extent, the sample was fully representative of the population. During the period, HF was responsible for 9% of total medical admission [19] a figure that is consistent with equivalent reports from other parts of Africa [14], [18], [20].

Data collection

A specific data extraction proforma was developed and used to obtain data on resource consumption in those cases enrolled in the Abeokuta HF registry. The clinical diagnostic criteria employed in the diagnosis of HF have been described elsewhere [19]. Clinical diagnoses were coded using the International Classification of Diseases (ICD-10) coding system [27]. The proforma was used to extract the following direct outpatient and inpatient cost categories as shown in the textbox below.

Health Care Expenditure

Direct Health Care Costs

The inpatient costs include the cost of medical and nursing care, cost of investigations and drugs ( ). It also includes the cost of surgery and procedures as well transportation to and from the hospital. Personnel costs include the opportunity cost of medical care, nursing as well as ancillary support by other health workers. The wages of these health workers were derived from the Federal Government of Nigeria salary scales. This included their basic salary; call duty allowance, hazard allowance and housing allowance. We did not capture cost associated with purchase of medications over the counter, cost of alternative medical care which is common in Africa, aids, home modifications etc. We assume that these categories are likely to represent a very small percentage of the total costs identified from this study. We also did not capture capital costs.
Table 1

Shows summary of the cost components.

Cost component
A.
B. In-patient care
i. Direct cost
Hospital care (Medical consultation)
Nursing care, utility fees, accommodation and feeding and ward consumables including oxygen)
Medications
Medications
Surgery and procedures
Transportation
Surgery and procedures
ii. Indirect cost- the days of lost work (productivity loss)
B. Out-patient care
i. Direct cost
Clinic visits
Laboratory investigations
Medications
Transportation
ii. Indirect cost-the days of lost work (productivity loss)

Indirect Health Care Costs

For indirect costs, the days of lost work (productivity loss) were calculated and the minimum wage used to monetize them.

In-patient cost

The standard costing table (unit costs) of the Federal Medical Center, Abeokuta for the year 2010 was used for computing the cost of consultations, hospital admissions, medical consumables, medical investigations, and drug therapy ( ). It was assumed that the cost of single hospital admission covers the cost of treatment in the emergency room as well as in the medical ward. The cost of medications was taken as a whole. We assumed that the cost of medications had remained unchanged throughout the year.

Out-patient costs

This was also grouped into direct and indirect costs. All the patients that were discharged alive were given monthly appointments for clinical review as well as for refill of their medications ( ).

Specific costs

Cost of drugs

The cost of drugs was based on the hospital's price list (which includes the tender prices plus a 10% mark up or dispensing fee). The frequency of use of the various categories of drugs was based on the findings from the HF registry. The most frequent dosage was used for cost calculation. We did not account for increase or reduction in dose of the drugs during the course of treatment. We assumed that substitution of one class or brand of medication occurred without additional costs.

Cost of Laboratory and diagnostic tests

The cost of all laboratory and diagnostic tests (haematological, biochemical, microbiological, chest radiography, electrocardiography and echocardiography) were based on the price list of the hospital in 2010. The rate of consumption of these items was also garnered from the HF registry.

Cost of Surgery and Procedures

The cost of surgeries and procedures were obtained from the Lagos State University Teaching Hospital (LASUTH), as well the Reddington multi-specialist hospital, Lagos where majority of the surgeries and procedures were performed [28], [29]. The surgeries and procedures include valve surgeries, coronary angioplasty/stenting, pericardiectomies etc. Total cost was multiplied by the frequency of the surgeries and procedures.

Estimation of indirect costs

The human capital approach was used to estimate the indirect cost. The average annual earning of the patients was estimated based on their occupational group. These were used to calculate their average daily earnings. The product of the working days lost and average daily earnings provided the productivity losses associated with HF in the study and these were assigned monetary values.

Cost analyses

All available costs (as detailed above) associated with in-patient care, out-patient care as well as the opportunity costs associated with HF management in the city were computed for the year 2010. An annual, prevalence based approach was employed in estimating the cost of the resources used for the management HF [10]–[12], [30]. Healthcare costs were then expressed in the local currency-Naira, (and converted to US Dollar [$US] at a rate of 150 Nigerian Naira to $US1 in 2010).

Results

Outpatient and inpatient costs were computed from a representative cohort of 239 HF cases over a 12-month period for the year 2010. provides a summary of the study cohort used to derive all HF-related health care activities. Mean age was 58.0±15.1 years, 46.9% were female and around one third were aged ≤55 years and in the prime of their potential working life.
Table 2

Sociodemographic profile of the HF subjects seen in 2010.

VariableValue
Gender
Male (n/%)127(53.1)
Female (n/%)112(46.9)
Mean age (years)58.0(15.1)
Median age(years)60
Age range (years)
<248(3.3)
25–3415(6.3)
35–4421(8.8)
45–5440(16.7)
55–6459(24.7)
65–7463(26.4)
> = 7533(13.8)
Marital status
Single32(13.4)
Married168(70.3)
Widow/widower5(2.1)
Separated/Divorced34(14.2)
Educational level
No formal education88(36.8)
Primary (< = 6 years)60(25.1)
Secondary (6–12 years)44(18.4)
Post-Secondary/University/Postgraduate (>12years)47(19.7)
Occupation
Unemployed20(8.4)
Unskilled labour146(61.1)
Skilled labour18(7.5)
Professional24(10.0)
Pensioner/Retiree31(13.0)
Place of residence
Within Abeokuta city138(57.7)
Outside Abeokuta but within Ogun State53(22.2)
Outside Abeokuta and outside Ogun State48(20.1)
Monthly Income of subjects in Naira(Median value)
Unemployed* 18000(120USD)
Unskilled labour90,000(600USD)
Skilled labour240,000(1600USD)
Professional480,000(3200USD)
Pensioner/Retiree330,000(2200USD)
Aetiology of HF
Hypertensive HF195(81.6)
Dilated Cardiomyopathy14(5.9)
Pericardial Diseases8(3.3)
Rheumatic Heart Disease4(1.7)
Others4(1.7)
Co-morbidities
Hypertension185(77.4)
Osteoarthritis49(20.9)
Atrial fibrillation37(15.5)
Diabetes Mellitus24(10.0)
Chronic Obstructive pulmonary disease7(2.9)
Others6(2.4)

*Allocated minimum wage in the country.

*Allocated minimum wage in the country.

Cost of components of in-patient care

Cost of hospital care

The following were computed for the subjects: medical consultation (N300/day), nursing care (N200/day), utility fees(N400/day), accommodation and feeding (N900/day) and average cost of ward consumables/patient/admission (N3500/patient)The estimated cost of hospital care for the year was about 5.5 million naira (about $U36,500).

Cost of laboratory investigations

The laboratory investigations considered in the costing is as shown in .The estimated cost was approximately 3.8 million naira (about $US28, 000).
Table 3

Cost of investigations (In-patient).

A. In-patient Investigations
Investigation Cost per test Percent Number Cost (Naira) Cost (US Dollars)
Urinalysis2008822545000300.0
Full blood count1350962293091502061.0
Blood sugar4009622991600610.7
Electrolyte and Urea2500962295725003816.7
Lipid profile3500651555425003616.7
Electrocardiography2500962295725003816.7
Echocardiography50009222011000007333.3
Chest X-Ray2000962294580003053.3
Cardiac enzyme50000.821000066.7
INR3500102484000560.0
HIV screening5004611155500370.0
Liver function tests3000501203600002400.0
Total Cost 3840750 28005.0
B. Out-patient investigations
Investigation Cost per test Percent* Number Cost (Naira) Cost (US Dollars)
Electrocardiography2500961974925003283.3
Electrolyte and Urea2500961974925003283.3
Total5000963949850006566.7

Note: Cost based on the hospital costing list for 2009.

Note: Calculation based on those that survived, it is assumed that same proportion on admission.

performed these investigations during follow up.

Note: Cost based on the hospital costing list for 2009. Note: Calculation based on those that survived, it is assumed that same proportion on admission. performed these investigations during follow up.

Cost of medications

This includes cost of standard drugs for the management of HF, as well as other drugs such as antituberculous drugs used for the management of T.B pericarditis. The estimated cost of drugs was N6, 565,527 (about $US43770) (see ).
Table 4

In-patient cost of medications.

DrugRouteDoseDosingUnit cost (Naira)Cost per daily dose(Naira)Total Cost(Naira)Number of subjectsTotal cost in US Dollars
FrusemideIV40 mg320601362022790.8
FrusemideOral40 mg3515340522722.7
AmlodipineOral5 mg11515615414.1
LisinoprilOral10 mg11515333022222.2
SpironolactoneOral25 mg11010203020313.5
DigoxinOral0.125 mg15510152036.8
CarvedilolOral6.25 mg12525550223.7
HydrallazineOral25 mg15590180.6
Isosorbide dinitrateOral10 mg122022039601826.4
Heparin (LMW)SC40 mg1135013502092501551395.0
WarfarinOral2.5 mg140401120287.5
AtorvastatinOral10 mg118018073804149.2
AmiodaroneOral200 mg2204020051.3
Antibiotics (Augmentin)IV600 mg360018003996002222664.0
Antibiotics (Augmentin)Oral625 mg217034075480222503.2
PrednisoloneOral30 mg13030717023947.8
Anti-tuberculous therapyOralMultiple drugs1606048083.2
AspirinOral75 mg1222081041.4
Total7295034863.4
Grand Total656552743770.2

Source: Federal Medical Centre, Abeokuta costing list, Median length of hospital stay = 9 days, 1 US Dollar  = 150 naira (2010).

Source: Federal Medical Centre, Abeokuta costing list, Median length of hospital stay = 9 days, 1 US Dollar  = 150 naira (2010).

Cost of Surgery/Procedures

As stated earlier, we estimated the cost of surgery/procedures for the few patients who were able to afford them. This was estimated to cost N1, 092, 000 (about $US72800) – see

Cost of transportation

This was calculated to cost N216, 600 (about $US1, 444) see

Indirect in-patient care cost

This was estimated to cost N17, 806,500 Naira ($US118, 710) – see .
Table 5

Indirect cost (In-patient/outpatient).

A. Indirect in-patient care cost
OccupationMonthly IncomeDaily incomeDaily income(Dollars)No of SubjectsTotal Income lost/day(Naira)Income lost (Naira)**Income lost (Dollar)**
Unemployed*18000900620180001620001080
Unskilled90000450030146657000591300039420
Skilled240000120008018216000194400012960
Professional4800002400016024576000518400034560
Pensioners3300001650011031511500460350030690
Total115800057900386239197850017806500118710
B. Indirect out-patient care cost
OccupationMonthly IncomeDaily incomeDaily income(Dollars)No of SubjectsTotal Income lost/day(Naira)Income lost (Naira)**Income lost (Dollar)**
Unemployed*18000900614126001512001008
Unskilled90000450030130585000702000046800
Skilled240000120008015180000216000014400
Professional4800002400016021504000604800040320
Pensioners3300001650011025412500495000033000
Total115800057900386205169410020329200135528

Note: Income loss was based on 5 working days in a week, **Income loss was based on median Los of 9 days.

Note: *Assigned the minimum wage in Nigeria, Income loss was based on 5 working days in a week,

Because most mortality occurred early, it was assumed that 205 subjects completed follow up, 1dollar  = 150Nigerian Naira.

Note: Income loss was based on 5 working days in a week, **Income loss was based on median Los of 9 days. Note: *Assigned the minimum wage in Nigeria, Income loss was based on 5 working days in a week, Because most mortality occurred early, it was assumed that 205 subjects completed follow up, 1dollar  = 150Nigerian Naira.

Cost of components of out-patient care

Out-patient clinic visit

This was based on the cost of medical consultations (N250/visit) and nursing/ancillary services (N200/visit). The calculated total cost was N29, 700 ($US198 US dollar) – see

Cost of out-patient investigations

This was calculated for subjects who survived initial hospital admission. It was assumed that the proportion of subjects who had these tests during admission were also able to have them done during the follow up period. It was estimated to cost N985, 000 ($US 6567 – see .

Cost of outpatient medications

This is shown in It was estimated to cost N9, 154,168 ($US61, 028).

Cost of outpatient transportation

This constituted a greater proportion of the out-patient care cost. It was calculated as N9, 717, 000 ($US 64,780) – see

Indirect out-patient care cost

This was estimated to cost about 20,329,200 Naira ($US135, 528) – see - .

Summary of in-patent and out-patient care cost

The total cost of in-patient care was estimated as N34, 996, 477 ($US301, 230). This comprised of N17, 899, 977 (50.9%, $US114, 600) and N17, 806,500 (49.1%, $US118, 710) for direct and in-direct costs respectively. Direct costs were responsible for 61% of in-patient care costs. About 40% of the direct cost was due to surgery/procedures. Hospitalization, medical investigations, drug therapy, and transportation accounted for 20%, 24%, 15%, and 1% respectively, of costs –see (A) and .
Table 6

Summary of various aspects of costs of in-patient/out-patient care.

A. Summary of various aspects of costs of in-patient care
ItemTotal cost (in Naira)Total Cost in US Dollars
Hospitalization547510036500.7
Investigations384075028005
Medications656552743770.2
Surgery and procedures1092000072800
Transportation2166001444
Total Direct Cost17189977114600
Total Indirect Cost17806500118710
Grand total 34996477 233310
B. Summary of various aspects of costs of out-patient care
ItemTotal cost (in Naira)Total Cost in US Dollars
Clinic visit11070007380
Investigations9850006567
Medications915416861028
Transportation971700064780
Total Direct cost20963168139754
Indirect cost20329200135528
Grand total 41292368 275282
Figure 1

Components of direct cost (In-patient).

summarizes the components and total estimated cost of out-patient care. It was estimated as N41, 292, 368 ($US 275,282 UD dollars). Direct and in-direct costs were N20, 963,168 ($US139, 754) and N20, 329,200 ($US135, 528) respectively, constituting 51% and 49% of total out-patient care costs. Transportation, medications, clinic visits and medical investigations contributed 46%, 44%, 5% and 5% respectively to these costs - see ( ).
Figure 2

Components of direct cost (out-patient).

Total cost

The total estimated cost of care of HF in Abeokuta for the year 2010 was N76, 288,845 ($US508, 595) translating to N319, 200 ($US2, 128) per patient per year. The proportional contribution of in-patient and out-patient cost were 46% and 54% respectively. The contribution of various components to the total cost is shown in .
Figure 3

Percentage contribution of different components to total cost.

Discussion

To our knowledge this is the first systematic attempt at estimating the cost of HF in Nigeria; a major populace of sub-Saharan Africa. We have calculated the cost from an individual perspective whilst calculating the total cost per annum overall from a societal perspective. Effort was made to capture all the HF patients in the city of Abeokuta during the study period. All cases of HF presenting to the two major hospitals in the city were captured into the database. Private health facilities, primary health centres as well as health workers were sensitized on the existence of the registry with good response. To a large extent, the sample was representative of the population. During the period, HF was responsible for 9% of total medical admission similar to earlier report from other parts of Africa [14], [18], [20]. The main findings of the study are - 1. The total cost of HF or cost per patient per year is enormous considering the context of a developing economy where out-of-pocket expenses is the main means of health care financing;2. Furthermore the estimated cost of HF was fairly distributed between in-patient and out-patient care; 3. A large proportion of direct cost for in-patient care was due to surgery and medical procedures and; 4. Out-patient medications and transportation was responsible for 90% of direct cost of out-patient care. The huge cost of HF has been well documented by several reports both at the individual and population levels. Data from the National Heart and Lung Institute of the United Kingdom shows that the cost of HF per person is approximately 8500 Pounds. At the national level HF costs about 39.2 billion US dollars in America (about 2% of US healthcare budget) [31]. Similar data have been reported from other countries [10], [11] [12], [32]. The distribution of cost of HF in our setting is different from that observed in high income countries [10], [11], [32] but similar to one report from Brazil [12]. There has not been any report from Africa to compare our findings with. The contribution of hospital care cost in these countries ranged from 53–75%. Cost of outpatient care was in the range of 4–31% while the cost of drug therapy was between 6–8% of the total cost of care. The pattern of heart diseases as well as level of technological development influences the mode of care as well as utilization of sophisticated and expensive medical equipment, procedures and consumables which are obviously needed for the care of HF patients. The consumption of these is higher in high income countries than in our setting. This is clearly shown by the impact of surgery/procedures on the cost of hospital care. The few cases (out of the many that needed this) that had surgery for valvular diseases or coronary interventions escalated the hospital care cost in our study. Other determinants of hospital cost will also include length of hospital stay [10], [13]. (in which our report is similar to European data but longer than the mean length of hospital stay in the USA) Cost of management of co-morbidities has also been shown to account for higher cost of hospitalization in high income countries. In one report on Medicare claims, HF accounted for only15% of the total in-patient cost while 57% were associated with other co-morbid conditions [33]. This may probably be responsible for the huge cost of hospitalization in high income countries compared to our environment. Due to lack of community based or nurse-led or home care of HF patients in our setting, our patients are given shorter out-patient appointments in order to refill their medications. This is responsible for the high cost attributable to transportation in our report. Because of the younger age of our subjects, HF in our setting is, therefore, associated with longer disability adjusted life years and by extension a huge cost to the society at large. With the changing demographic and epidemiological landscape in Nigeria coupled with the rising burden of cardiovascular risk factors and non-communicable diseases (especially hypertension) in the country, the rate of HF is predicted to rise if preventive measures are not put in place at all levels. This will put a lot of strain in an already weak health system. The high cost of surgical interventions and procedures is out of the reach of the average Nigerian. Prevention of conditions requiring this mode of care such as rheumatic heart disease, tuberculosis (because of pericarditis) and coronary artery disease should be a priority for the country at large. Furthermore the need for a functional, effective and efficient social health insurance system in the country cannot be overemphasized considering the fact that majority of those afflicted by HF are poor and are not likely to sustain the treatment of their illness for a long time. There is also need to develop community based HF care in the country as this will reduce the cost of outpatient care which is largely contributed by the cost of frequent transport to-and-from the health facility.

Limitations

This is a hospital based study. Although we tried as much as possible to capture all the HF cases in the city during the study period, there is still the possibility that mild cases may have been missed out especially those that were managed in the out-patient clinic. We also did not assess cost based on the severity of HF (NYHA class). Studies have shown that those in NYHA class IV were 8–30 times more expensive to manage compared to those in NYHA class II [30], [34], [35]. Age and sex-specific cost analysis was also not carried out. We also did not include the cost of co-morbidities neither did we capture cost due to alternative medicines (which is common in Africa), over the counter purchases, capital cost and indirect cost by care givers as well as the general cost to the society. These are potential areas of research in our community in the future.

Conclusion

Our data shows the profound impact and importance of HF as a major public health problem in a developing economy like Nigeria that is still battling with communicable diseases. The annual individual cost of HF is high coupled with the fact that of pocket expenses in the country is over 90%. There is therefore need to reduce this expenditure through control of risk factors for HF in the society especially high blood pressure, reduction in hospital as well as out-patient care cost through the development of community HF care programmes in the country. Cost of procedures (In-patient). (DOCX) Click here for additional data file. Cost of transport (In-patients). (DOCX) Click here for additional data file. Cost of clinic visits (Out-patient). (DOCX) Click here for additional data file. Cost of medications (Out-patient). (DOCX) Click here for additional data file. Cost of transport (Out-patient). (DOCX) Click here for additional data file.
  27 in total

1.  DECLARATION OF HELSINKI. RECOMMENDATIONS GUIDINGS DOCTORS IN CLINICAL RESEARCH.

Authors:  I A RITS
Journal:  World Med J       Date:  1964-09

2.  Financial aspects of heart failure programs of care.

Authors:  Simon Stewart
Journal:  Eur J Heart Fail       Date:  2005-03-16       Impact factor: 15.534

3.  [Management, cost and mortality of a cohort of patients with advanced heart failure (the EPICAL study)].

Authors:  F Fagnani; L Buteau; J M Virion; S Briançon; F Zannad
Journal:  Therapie       Date:  2001 Jan-Feb       Impact factor: 2.070

Review 4.  The pharmacoeconomics of ACE inhibitors in chronic heart failure.

Authors:  J McMurray; A Davie
Journal:  Pharmacoeconomics       Date:  1996-03       Impact factor: 4.981

5.  Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study.

Authors:  A Mosterd; A W Hoes; M C de Bruyne; J W Deckers; D T Linker; A Hofman; D E Grobbee
Journal:  Eur Heart J       Date:  1999-03       Impact factor: 29.983

6.  Clinical and socio demographic aspects of congestive heart failure patients at Kenyatta National Hospital, Nairobi.

Authors:  G O Oyoo; E N Ogola
Journal:  East Afr Med J       Date:  1999-01

7.  Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995.

Authors:  K MacIntyre; S Capewell; S Stewart; J W Chalmers; J Boyd; A Finlayson; A Redpath; J P Pell; J J McMurray
Journal:  Circulation       Date:  2000-09-05       Impact factor: 29.690

8.  The health care costs of heart failure in Sweden.

Authors:  T Rydén-Bergsten; F Andersson
Journal:  J Intern Med       Date:  1999-09       Impact factor: 8.989

9.  Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic.

Authors:  Margaret M Redfield; Steven J Jacobsen; John C Burnett; Douglas W Mahoney; Kent R Bailey; Richard J Rodeheffer
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

10.  Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; Data from the Swedish Hospital Discharge Registry 1988 to 2000.

Authors:  Maria Schaufelberger; Karl Swedberg; Max Köster; Måns Rosén; Annika Rosengren
Journal:  Eur Heart J       Date:  2004-02       Impact factor: 29.983

View more
  13 in total

1.  A Systematic Review of Direct Cardiovascular Event Costs: An International Perspective.

Authors:  Steve Ryder; Kathleen Fox; Pratik Rane; Nigel Armstrong; Ching-Yun Wei; Sohan Deshpande; Lisa Stirk; Yi Qian; Jos Kleijnen
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

Review 2.  An overview of heart failure in low- and middle-income countries.

Authors:  Valirie N Agbor; Ntobeko A B Ntusi; Jean Jacques Noubiap
Journal:  Cardiovasc Diagn Ther       Date:  2020-04

3.  Systematic review of economic burden of heart failure.

Authors:  Asrul Akmal Shafie; Yui Ping Tan; Chin Hui Ng
Journal:  Heart Fail Rev       Date:  2018-01       Impact factor: 4.214

Review 4.  Epidemiology and aetiology of heart failure.

Authors:  Boback Ziaeian; Gregg C Fonarow
Journal:  Nat Rev Cardiol       Date:  2016-03-03       Impact factor: 32.419

5.  The economic burden of chronic non-communicable diseases in rural Malawi: an observational study.

Authors:  Qun Wang; Stephan Brenner; Olivier Kalmus; Hastings Thomas Banda; Manuela De Allegri
Journal:  BMC Health Serv Res       Date:  2016-09-01       Impact factor: 2.655

6.  Cardiology-cardiothoracic subspeciality training in South Africa: a position paper of the South Africa Heart Association.

Authors:  Karen Sliwa; Liesl Zühlke; Robert Kleinloog; Anton Doubell; Iftikhar Ebrahim; Mohammed Essop; Dave Kettles; David Jankelow; Sajidah Khan; Eric Klug; Sandrine Lecour; David Marais; Martin Mpe; Mpiko Ntsekhe; Les Osrin; Francis Smit; Adriaan Snyders; Jean Paul Theron; Andrew Thornton; Ashley Chin; Nico van der Merwe; Erika Dau; Andrew Sarkin
Journal:  Cardiovasc J Afr       Date:  2016 May/Jun       Impact factor: 1.167

7.  Data on the epidemiology of heart failure in Sub-Saharan Africa.

Authors:  Ulrich Flore Nyaga; Jean Joel Bigna; Valirie N Agbor; Mickael Essouma; Ntobeko A B Ntusi; Jean Jacques Noubiap
Journal:  Data Brief       Date:  2018-02-12

8.  Indirect costs and public finance consequences of heart failure in Poland, 2012-2015.

Authors:  Błażej Łyszczarz
Journal:  BMC Public Health       Date:  2018-09-19       Impact factor: 3.295

9.  Cost-of-illness studies in heart failure: a systematic review 2004-2016.

Authors:  Wladimir Lesyuk; Christine Kriza; Peter Kolominsky-Rabas
Journal:  BMC Cardiovasc Disord       Date:  2018-05-02       Impact factor: 2.298

10.  Clinical Characteristics and Factors Associated with Heart Failure Readmission at a Tertiary Hospital in North-Eastern Tanzania.

Authors:  Abid M Sadiq; Nyasatu G Chamba; Adnan M Sadiq; Elichilia R Shao; Gloria A Temu
Journal:  Cardiol Res Pract       Date:  2020-04-30       Impact factor: 1.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.